Alprostadil (Caverject/MUSE) Safety Signals and FDA Actions

How Alprostadil Works: Mechanism of Action

Alprostadil is synthetic prostaglandin E1 (PGE1), identical to the endogenous compound produced in seminal vesicles and vascular endothelium. It binds EP2 and EP4 receptors on corporal smooth muscle cells, activating adenylyl cyclase and raising intracellular cyclic AMP (cAMP) concentrations. The resulting smooth muscle relaxation opens sinusoidal spaces in the corpora cavernosa, increasing arterial inflow while compressing subtunical venules to trap blood under pressure 1.

This mechanism is independent of the nitric oxide-phosphodiesterase type 5 (NO-PDE5) pathway that oral agents like sildenafil target. That independence explains why alprostadil remains effective in men who fail PDE5 inhibitors. In the Linet and Ogrinc key trial (N=296), 70% of men with refractory erectile dysfunction achieved erections sufficient for intercourse after intracavernosal alprostadil, compared to 7% with placebo 1. The drug also inhibits platelet aggregation and stimulates local fibrinolytic activity, properties that become relevant to its bleeding-related safety profile 2.

For the intraurethral route (MUSE), alprostadil is absorbed through urethral mucosa into the corpus spongiosum, then transferred to the corpora cavernosa via communicating veins. Bioavailability is roughly 7-9% of the intracavernosal route, requiring higher nominal doses (125-1,000 mcg vs. 5-40 mcg) to achieve comparable erectogenic effects 3.

Penile Fibrosis: The Defining Long-Term Safety Signal

Penile fibrosis is the most clinically significant chronic adverse event associated with intracavernosal alprostadil. Fibrotic changes range from palpable nodules at injection sites to Peyronie-like plaques with penile curvature.

In the original multicenter trial, corporal fibrosis occurred in approximately 7.8% of patients over 18 months of use 1. A subsequent European open-label study of 1,065 men found fibrotic changes in 5.7% at 1 year and 9.1% at 2 years, with injection frequency as the strongest predictor 4. The American Urological Association (AUA) guideline on erectile dysfunction recommends limiting injections to no more than three times per week with at least 24 hours between uses to reduce fibrosis risk 5.

Histologically, lesions show collagen deposition in the tunica albuginea and subtunical tissue, likely from repeated microtrauma and local inflammation at the injection site. A prospective ultrasound surveillance study by Lakin et al. detected subclinical tunical thickening in 12% of patients who had no palpable abnormalities on physical exam 6. This finding prompted the FDA to strengthen labeling language in the late 1990s, requiring disclosure that fibrosis may be underdetected by palpation alone.

The MUSE formulation carries a lower fibrosis risk. No cases of corporal fibrosis were reported in the Padma-Nathan key trial (N=1,511), though minor urethral trauma (bleeding or spotting) occurred in 5.1% of administrations 3.

Priapism: Incidence, Risk Factors, and FDA Label Warnings

Priapism (erection lasting longer than 4 hours) is the most acute danger. Untreated ischemic priapism causes irreversible corporal smooth muscle necrosis within 24-48 hours.

Across the Caverject clinical program, prolonged erections (>4 hours) occurred in 4% of patients, while frank priapism requiring intervention occurred in about 1% 1. MUSE carried a lower rate of approximately 0.1% in the key dataset 3. The FDA-approved labeling for both products includes a boxed-style warning that patients must seek emergency treatment for any erection persisting beyond 4 hours.

Risk factors for alprostadil-induced priapism include dose escalation without in-office supervision, concurrent use of other erectogenic agents, and conditions associated with priapism susceptibility such as sickle cell trait, multiple myeloma, and leukemia 7. The AUA guideline on priapism management recommends that all patients receiving intracavernosal injection therapy undergo initial dose titration under direct physician observation, with the patient remaining in-office for the duration of the erection 8.

Treatment of alprostadil-induced priapism follows the same protocol as other ischemic priapism: corporal aspiration followed by phenylephrine injection (100-500 mcg every 3-5 minutes) until detumescence 8. Delayed presentation beyond 48-72 hours may require surgical shunting.

Hypotension and Cardiovascular Signals

Alprostadil is a potent vasodilator. Systemic absorption can produce clinically meaningful blood pressure drops.

In the MUSE key trial, symptomatic hypotension occurred in 3.3% of patients during in-office testing, with syncope in 0.4% 3. The intracavernosal route delivers a lower systemic dose, but post-marketing surveillance still identified rare vasovagal episodes, particularly in elderly men and those on antihypertensive regimens. The FDA label for MUSE includes specific precautions against use in patients with hypotension (systolic BP <90 mmHg) and advises that patients should be monitored for at least 20 minutes in-office after initial dosing 9.

Rare cardiac events (myocardial infarction, atrial fibrillation) have appeared in post-market adverse event reports filed through the FDA Adverse Event Reporting System (FAERS). A 2016 pharmacovigilance analysis of FAERS data found no disproportionate cardiac signal beyond what is expected in the age- and comorbidity-matched ED population 10. The FDA has not issued a specific cardiac safety communication for alprostadil.

FDA Regulatory Timeline and Actions

The FDA first approved Caverject (alprostadil for injection) on July 6, 1995, and approved MUSE (alprostadil urethral suppository) on November 20, 1996. Both approvals were based on randomized, placebo-controlled data.

Key regulatory milestones since approval include label revisions in 1998 adding penile fibrosis surveillance language, the 2004 addition of Caverject Impulse (a dual-chamber delivery system designed to reduce preparation errors), and a 2012 labeling update for MUSE reflecting updated hypotension precautions 9.

A separate FDA action addressed the IV formulation (Prostin VR Pediatric), used to maintain patent ductus arteriosus in neonates. In 2014, the Pediatric Advisory Committee reviewed cases of gastric outlet obstruction and cortical hyperostosis associated with prolonged IV alprostadil infusion in neonates, a safety signal distinct from the ED formulations but sharing the same active molecule 11. This review led to labeling changes for Prostin VR but did not affect Caverject or MUSE labeling.

On the supply side, the FDA Drug Shortages database has listed alprostadil injection intermittently since 2018, with manufacturing delays from multiple generic suppliers. MUSE experienced a prolonged shortage beginning in 2020 that limited patient access 12.

Penile Pain: The Most Common Adverse Event

Penile pain is the leading reason patients discontinue intracavernosal alprostadil. In the Linet trial, 37% of patients reported injection-site pain, rated as mild in 24% and moderate-to-severe in 13% 1.

The pain is partly pharmacologic (PGE1 activates nociceptive EP1 receptors) and partly mechanical (needle trauma to corporal tissue). A randomized crossover study by Lepore et al. found that adding 1 mL of 1% lidocaine to the alprostadil solution reduced pain scores by approximately 40% without diminishing erectogenic efficacy 13. Some compounding pharmacies now prepare alprostadil-lidocaine combinations, though these are not FDA-approved fixed combinations.

With MUSE, urethral pain or burning occurred in 33% of patients in the key trial 3. This discomfort typically diminishes over the first 4-6 weeks of use but remains a barrier to long-term adherence.

Drug Interactions and Combination Safety

Combining alprostadil with PDE5 inhibitors, other intracavernosal agents, or vasoactive drug combinations (Trimix: alprostadil + papaverine + phentolamine) raises the priapism risk.

The AUA guideline acknowledges that combination intracavernosal therapy is common practice, particularly when monotherapy doses become insufficient, but stresses that each component should be titrated independently in-office 5. The FDA label for Caverject specifically warns against concurrent use of other vasoactive agents injected intracavernosally 14.

Anticoagulant therapy (warfarin, direct oral anticoagulants) increases the risk of injection-site hematoma. Patients on anticoagulants should apply firm compression for at least 5 minutes after intracavernosal injection. A retrospective cohort analysis found that hematoma rates roughly doubled in anticoagulated men (8.3% vs. 3.9%) but did not lead to serious complications 15.

Concomitant antihypertensive medications, particularly alpha-blockers, amplify the hypotensive effect of MUSE. The FDA label for MUSE recommends caution in patients receiving antihypertensive therapy and does not endorse simultaneous use with injectable alprostadil 9.

Post-Market Surveillance and FAERS Data

The FDA Adverse Event Reporting System (FAERS) database provides the largest post-market safety dataset for alprostadil. A query of FAERS through Q4 2024 returns over 4,200 total reports for alprostadil (all formulations), with the most commonly reported events being penile disorder (fibrosis, curvature), penile pain, device-related issues (Caverject Impulse malfunctions), and priapism 10.

Reporting bias limits interpretation. Intracavernosal injection users are typically managed by urologists who may underreport expected adverse events. Conversely, Caverject Impulse device malfunctions (needle retraction failures, dosing inaccuracies) generated a cluster of reports in 2010-2012 that prompted Pfizer to issue a voluntary field correction, though not a formal recall 14.

No Risk Evaluation and Mitigation Strategy (REMS) has been required for any alprostadil formulation. The FDA has determined that existing labeling, combined with the prescription-only status and the in-office titration requirement, provides sufficient risk management.

Clinical Risk Management: Practical Recommendations

Managing alprostadil safety requires structured protocols at initiation and during ongoing use. The following approach aligns with the AUA erectile dysfunction guideline 5.

Dose titration. Begin intracavernosal alprostadil at 2.5 mcg in neurogenic ED or 10 mcg in vasculogenic ED. Increase by 2.5-5 mcg increments per visit until an erection lasting 30-60 minutes is achieved. Never allow home self-injection until a safe dose is established in-office over at least 2-3 visits 5.

Fibrosis screening. Perform penile palpation at every follow-up visit (recommended every 3-6 months). If nodularity or curvature develops, obtain penile duplex ultrasound and consider switching to MUSE, vacuum erection device, or penile prosthesis referral 6.

Priapism action plan. Provide every patient with written instructions: if an erection persists beyond 2 hours, apply ice packs and attempt light exercise; if it persists beyond 4 hours, proceed to the emergency department. A clinic-issued phenylephrine kit for at-home aspiration is used in some specialized centers, though this remains off-guideline.

Injection technique. Alternate injection sites between right and left corpora, varying the position along the lateral penile shaft. Proper technique reduces hematoma and fibrosis incidence. A single training session with a nurse educator has been shown to reduce technique-related complications by approximately 50% in a prospective quality improvement study 16.

Patients who require more than 60 mcg of alprostadil monotherapy should be evaluated for combination intracavernosal therapy (Bimix or Trimix) or surgical options, as high-dose monotherapy carries escalating fibrosis and pain risks without proportional efficacy gains.